Environment
Organizational Structure
organization and global prEsEncE of thE Morphosys group
MorphoSys AG and its subsidiaries develop and commercialize high-quality antibodies for therapeutic as well as for research and diagnostic applications based on the Company’s industry-lead- ing proprietary technologies. MorphoSys operates in three busi- ness segments. Partnered Discovery generates significant value for the Company by developing drug candidates for commercial partners. This segment handles various therapeutic development programs in alliances with renowned biotechnology and pharma- ceutical companies. The second segment, Proprietary Development, also operates in the therapeutic market. The goal of this segment
fig. 1: organizat ional struc turE of thE Morphosys group
therapeutic antibodies
partnered discovery proprietary development
Morphosys ag
Segments
Fields of Use
research and diagnostics abd serotec
39
Operations and Business Environmentf in a n c ia l s t a t E M E n t s
MorphoSys carefully considers locational advantages such as good infrastructure, a qualified workforce, political support for biotech- nology and life sciences, synergies resulting from cooperation with regional research institutes, and a broadly based environment of suppliers in order to support its future growth objectives. lEgal structurE of thE Morphosys group
GROUP MANAGEMENT AND SUPERVISION
MorphoSys AG, a German stock corporation listed in the Prime Standard segment on the Frankfurt Stock Exchange, heads the MorphoSys Group. In accordance with the German Stock Corpora- tion Act, MorphoSys AG has a dual-board structure. The Company
is managed by a Management Board whose four members are ap- pointed and directed by the Supervisory Board. For more infor- mation regarding management and supervision as well as corpo- rate governance in general, please see the Corporate Governance Report on page 81. The Senior Management Group, composed of 13 people, represents the different MorphoSys departments and completes the MorphoSys management team. In the year under review, there have been no changes to the legal structure of the MorphoSys Group or its entities compared to the year before. oxford
Martinsried raleigh
düsseldorf
puchheim fig. 2: WorldWidE locat ions of thE Morphosys group
r&d g&a WarEhousE salEs Manufac t uring sEE gl ossary
s e e pag e 15 2 cross-rEfErEncEs e e pag e 8 1
g r o u p M a n a g E M E n t r E p o r t
40
NEW MEMBER OF THE MANAGEMENT BOARD
In the first quarter of 2011, MorphoSys announced a change to its Management Board, with Jens Holstein joining the Company from Fresenius Kabi. He succeeded Dave Lemus both as Chief Financial Officer of MorphoSys AG and as a member of the Management Board (Vorstand). Jens Holstein took up his position on May 1, 2011. businEss actiVitiEs
MORPHOSYS TECHNOLOGIES
MorphoSys’s protein engineering capabilities are the foundation of its success. The Company’s most successful technology to date is the HuCAL platform, a collection of several billion distinct, fully human antibodies for the in vitro generation of highly specific antibodies. This recombinant antibody technology has enabled the generation of therapeutic and diagnostic antibodies, including those binding to difficult antigens, for over ten years now. The re- sulting product pipeline is one of the industry’s broadest and is continuously progressing. Currently, 76 therapeutic HuCAL-derived programs are in development, with several antibodies thereof be- ing studied in multiple indications.
Through the acquisition of Sloning BioTechnology GmbH in Octo- ber 2010, MorphoSys has become the sole source of Slonomics, a technology which dramatically improves the assembly and quality of protein libraries. The fully automated genetic engineering plat- form utilizes sets of double-stranded DNA triplets for the controlled fabrication of highly diverse combinatorial gene libraries. This combinatorial technology enables researchers to increase the suc- cess rate of their screening for new and optimized therapeutic anti- bodies, proteins or industrial enzymes.
In December 2011, MorphoSys unveiled the next-generation anti- body technology, Ylanthia. Being one of the industry’s largest anti- body libraries to date, it uses a novel concept for the in vitro gen- eration of highly specific and fully human antibodies. The unique Ylanthia technology was specifically conceived and designed to overcome current limitations in therapeutic antibody development, such as poor biophysical properties or limited diversity. If required, antibodies from the Ylanthia library can be additionally optimized using Slonomics technology. This feature distinguishes Ylanthia
from the HuCAL platform, which relies on a modular gene design
and preformed cassettes for antibody optimization.
MORPHOSYS IN THE THER APEUTIC MARKET
MorphoSys is a leading provider of superior antibody technologies in the therapeutic market, above all through HuCAL, one of the most successful antibody libraries in the industry. The Company addresses the market through alliances with pharmaceutical and biotechnology companies, as well as through proprietary develop- ment activities. As a biopharmaceutical company, MorphoSys has an outstanding profile as it is able to finance all proprietary R&D activities through its own cash flows while recording solid operat- ing profits.
COMPETITIVE L ANDSCAPE
The market for therapeutic antibodies is still one of the most valu- able and fastest-growing in human healthcare. Driven by acqui- sitions, there has been a rising concentration on a small number of key technology providers over the past few years. Pharmaceutical and biotechnology companies are striving to gain access to new pipeline opportunities through M&A and in-licensing activities. This need for innovative product replenishment offers great pros- pects for companies like MorphoSys which are able to develop progressive antibody technology platforms. A major challenge how- ever, especially for smaller biotechnology developers in this field, are the limited financial capacities.
According to research company Datamonitor, more than 300 mono- clonal antibody candidates are in clinical development, with an equal number of programs (around 140 each) in phase 1 and phase 2 clinical development, 37 candidates in late-stage (phase 3) clini- cal development, and 3 candidates in preregistration. Oncology accounts for the highest number of programs in clinical develop- ment, with around half of all programs of the development process. After oncology, the second-largest therapy area includes autoim- mune and inflammatory diseases, with a total of 70 monoclonal antibodies in clinical development. The third-best represented therapy area is infectious diseases with a total of 26 programs in phase 1 clinical trials.
sEE gl ossary
s e e pag e 15 2 sEE gl ossarys e e pag e 15 2